Free Trial
OTCMKTS:CVALF

Covalon Technologies (CVALF) Stock Price, News & Analysis

$2.39
-0.02 (-0.83%)
(As of 09/18/2024 ET)

About Covalon Technologies Stock (OTCMKTS:CVALF)

Key Stats

Today's Range
$2.35
$2.39
50-Day Range
$1.51
$2.41
52-Week Range
$0.73
$2.43
Volume
29,452 shs
Average Volume
11,079 shs
Market Capitalization
$59.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.

Receive CVALF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covalon Technologies and its competitors with MarketBeat's FREE daily newsletter.

CVALF Stock News Headlines

Kamala Harris and The Woke Progressive Nightmare
New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.
Covalon Announces First Quarter Fiscal 2024 Results
See More Headlines

CVALF Stock Analysis - Frequently Asked Questions

Covalon Technologies' stock was trading at $0.77 on January 1st, 2024. Since then, CVALF shares have increased by 210.4% and is now trading at $2.39.
View the best growth stocks for 2024 here
.

Covalon Technologies Ltd. (OTCMKTS:CVALF) released its quarterly earnings results on Wednesday, August, 21st. The company reported $0.04 EPS for the quarter. The company earned $6.74 million during the quarter. Covalon Technologies had a negative trailing twelve-month return on equity of 4.56% and a negative net margin of 2.94%.

Shares of CVALF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
8/21/2024
Today
9/18/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
OTCMKTS:CVALF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-3,310,000.00
Pretax Margin
-10.55%

Debt

Sales & Book Value

Annual Sales
$19.72 million
Book Value
$0.56 per share

Miscellaneous

Free Float
N/A
Market Cap
$59.91 million
Optionable
Not Optionable
Beta
-0.35
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

This page (OTCMKTS:CVALF) was last updated on 9/19/2024 by MarketBeat.com Staff
From Our Partners